Abstract
We describe three adolescent patients on chronic hemodialysis with a pubertal growth spurt who developed severe hyperparathyroidism during recombinant human growth hormone treatment. Parathyroid hormone levels were raised in parallel with the increase in linear growth in all patients. In two patients, hyperparathyroidism was successfully controlled with an increase in calcitriol dosage. In the third patient, growth hormone had to be withdrawn. We discuss the possibility that puberty is a risk factor for the development of hyperparathyroidism during growth hormone therapy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Additional information
Received: 2 September 1998 / Revised: 28 April 1999 / Accepted: 3 May 1999
Rights and permissions
About this article
Cite this article
Picca, S., Cappa, M. & Rizzoni, G. Hyperparathyroidism during growth hormone treatment: a role for puberty?. Pediatr Nephrol 14, 56–58 (2000). https://doi.org/10.1007/s004670050014
Issue Date:
DOI: https://doi.org/10.1007/s004670050014